The United States Food and Drug Administration (FDA) has officially expanded the approved indication for Bristol Myers Squibb’s (BMS) flagship…
Read More
Akeso Secures NMPA Approval for Gumokimab to Treat Plaque Psoriasis in China
Akeso has announced a significant milestone in its therapeutic pipeline with the National Medical Products Administration (NMPA) of China granting…
Read More
Climate change could increase hard-to-treat bacterial infections
A groundbreaking study published on April 22 in the prestigious journal Nature has revealed a potentially alarming consequence of climate…
Read More
OrsoBio’s LXR Inverse Agonist Shows Promise for Hard-to-Treat Triglyceride Disorders, Paving New Path Beyond GLP-1 Dominance
OrsoBio, a specialized biotechnology firm dedicated to pioneering therapies for obesity and its associated metabolic conditions, is strategically charting a…
Read More
OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders
OrsoBio, a specialized biotechnology company strategically focused on addressing obesity and its myriad related metabolic dysfunctions, is charting a course…
Read More
OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders
OrsoBio, a specialized biotechnology firm dedicated to pioneering treatments for obesity and its associated metabolic disorders, is strategically charting a…
Read More
Rubedo Life Sciences Pioneers Senolytic Approach to Reverse Skin Aging and Treat Inflammatory Dermatoses
In a significant shift within the pharmaceutical and longevity sectors, Rubedo Life Sciences, under the leadership of CEO Dr. Frederick…
Read More
OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders and pioneering a new frontier in obesity therapeutics
OrsoBio, a dynamic biotech enterprise dedicated to advancing novel therapies for obesity and a spectrum of obesity-related metabolic disorders, is…
Read More
